Last week, on the cover of @NatureAging, we published the first computational framework for epigenetic age estimation at single-cell resolution. A fantastic collaboration with @CsabaKerepesi and @VadimGladyshev in the @gladyshev_lab @harvardmed! nature.com/articles/s43587-0… 1/🧵

Embryo selection. But, for we the living, brain cell replacement is an ambitious path worth developing further.

We started a new program at @RetroBio_ to explore what can be achieved by going deep on combinations of small molecules to achieve rejuvenation. Incepted by me and led by @z_chiang

Hans Zimmer performing the main theme from “Man of Steel” live in concert. Goosebumps.

Sustained epigenetic rejuvenation of serially engrafting human iPSC-derived HSCs biorxiv.org/content/10.64898…

was initially quite skeptical of "industry PhDs" but Arjun is one of the most prolific scientists I've worked with many people assume that iPSC therapies are just for replacing lost cells, but here we show we can rejuvenate the system that forms ~80% of human cells!

I’m excited to share the first paper from my PhD research at @RetroBio_ (and my first paper as first author) - now on bioRxiv! Can we take adult human cells, turn them into blood-forming stem cells, and build a new blood system that is both functional and molecularly young? Our preprint: biorxiv.org/content/10.64898…

Sustained molecular rejuvenation demonstrated in serially transplanted iHSCs (stem-cell-derived blood generating cells) -- a new preprint from @RetroBio_

I'm hiring a CMC Regulatory Lead to drive CMC Regulatory strategy and execution at Retro. This is an opportunity to join a fast-rising, early-stage biotech backed by Sam Altman that is developing therapeutics that target the fundamental drivers of aging to treat and prevent multiple downstream age-related diseases. Our pipeline is unusually broad for a company at our stage: cell and gene therapies, small molecules, and AI-designed protein therapeutics. For someone who loves the craft of CMC regulatory work, this is a chance to work at real technical depth across multiple therapeutic modalities and help build something important. jobs.lever.co/retro/2f9b3bc9…

really enjoyed being a part of this conversation - with therapies now starting to target the upstream cause (aging) of multiple downstream serious diseases, there is so much opportunity for us to unlock over the next decade some things worth considering: non-legislative - an FDA center of excellence for healthspan products - application of accelerated approval to therapies targeting age-related diseases and multimorbidity legislative - Multi-Disease Therapeutic Designation to enable cross-division communication with FDA for multimorbidity registrational plans - THRIVE Act tiered-approval approach for healthspan products

Russia has committed $26 billion to longevity science, while China is advancing large-scale stem cell anti-aging trials and expanding aggressive investment in regenerative medicine and longevity biotechnology. Scientific leadership in longevity is rapidly becoming a defining frontier of global competitiveness. The United States cannot afford to sit on the sidelines. Join our letter campaign: actionnetwork.org/letters/th…

Retro Biosciences, the longevity startup backed by OpenAI CEO Sam Altman, has raised more money at a $1.8 billion valuation, it announced Friday. trib.al/pM1QX6F

We raised $$! retro.bio/blog/fundraise-202…

“The logical thing to do is to use conventional equipment in an unconventional way to get to scale, and then start modifying the equipment to increase the rate”

Charts of the week substack.com/home/post/p-192…

Systemic epigenetic dysregulation as a driver of ageing and a therapeutic target nature.com/articles/s41580-0…

New Online! Systemic epigenetic dysregulation as a driver of ageing and a therapeutic target dlvr.it/TRknlS

I've noticed a lot of renewed interest in drug repurposing lately, so I wrote up one of my favorite examples: the BCG vaccine Every year, tens of thousands of Americans get a tuberculosis vaccine poured into their bladder to treat cancer -- and it works really well -- and the story of how that became standard medical practice is pretty fun.